Pink Sheet Podcast: BrainStorm’s ALS Adcomm, Batch Testing Imported Drugs, US FDA’s First In-Person Meeting
Executive Summary
Pink Sheet reporters and editors discuss the FDA’s upcoming advisory committee meeting for the controversial ALS cell therapy NurOwn, a proposal to batch test all drugs coming into the US amid problems conducting foreign inspections, and the FDA’s return to in-person meetings with industry.
You may also be interested in...
Pink Sheet Podcast: Big Pharma’s US FDA Scorecard, Sarepta’s DMD Gene Therapy Delay, US FDA Adcomm Reforms
Pink Sheet reporters and editors discuss the largest pharma companies’ pending applications, the FDA delaying its decision on Sarepta’s gene therapy in Duchenne muscular dystrophy, and a plan to add more temporary members to agency advisory committees … as well as a little bit of “The Simpsons.”
Supplemental Filings: Califf Discusses Revolving Door; Poll Examines Public Trust In FDA Approvals
Commissioner expresses concern about agency lawyers leaving and then representing US FDA’s opponents in court. Also, as lawsuits about abortion pill continue, KFF finds the public trusts FDA more than the judiciary on determining products’ safety and effectiveness.
Supplemental Filings: FDA Can't 'Plug' All Shortage Holes, New Jobs For Billy Dunn, Lisa Parks & Heidi Rebello
From infant formula to drugs, Califf can't get away from shortage work. Plus, the revolving door brings new jobs for some top pharma folks.